New drug combo shows early promise against Hard-to-Treat cancers
NCT ID NCT06091930
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug called BI 765049, alone or combined with another drug (ezabenlimab), in 21 Asian adults with advanced solid tumors (stomach, colorectal, pancreatic, liver, head and neck, or lung cancer) that have a specific marker called B7-H6. The main goals were to find a safe dose and see if the drugs could shrink tumors. Participants received infusions every three weeks for up to three years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 765049 and ezabenlimab
What this could lead to
If it works, this could point toward a new treatment option for advanced cancers that have the B7-H6 marker.
What could go wrong
This is a very early Phase 1 trial with only 21 participants, so it is too small to prove effectiveness. The drugs may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Japanese Foundation for Cancer Research
Tokyo, Koto-ku, 135-8550, Japan
-
National Cancer Center Hospital
Tokyo, Chuo-ku, 104-0045, Japan
-
National Cancer Center Hospital East
Chiba, Kashiwa, 277-8577, Japan
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Severance Hospital
Seoul, 03722, South Korea
-
Shanghai East Hospital
Shanghai, 200120, China